Urothelial Cancer | Specialty

Real-World Data Support Nadofaragene Firadenovec Use in BCG-Unresponsive NMIBC: With Jacob Moyer, BS; and Mark D. Tyson, II, MD, MPH

May 1st 2025

Oncology Experts Highlight the Key Data and Top Abstracts From AUA 2025

May 1st 2025

Experts revisit the most intriguing abstracts and data they saw presented at the 2025 American Urological Association Annual Meeting.

Subgroup Analysis Shows No Key Differences Between High-Grade Recurrence, Cancer Progression Outcomes in BCG-Unresponsive NMIBC

April 30th 2025

Among 3 subgroups of patients with BCG-unresponsive NMIBC, no significant clinical differences were identified regarding rates of high-grade recurrence.

Cancer Vaccines Begin to Take Center Stage With Investigators Anticipating an Even Brighter Future

April 30th 2025

Expert investigators discuss the current and future landscape of cancer vaccine development in various tumor types.

Padeliporfin VTP Therapy Yields Complete Responses With Manageable Safety in Low-Grade, Upper Tract Urothelial Cancer

April 29th 2025

Padeliporfin vascular targeted photodynamic therapy was safe and generated responses in low-grade, upper tract urothelial cancer.

Dr Guerrero-Ramos on the Potential Role of TAR-200 in BCG-Unresponsive Papillary NMIBC

April 29th 2025

Felix Guerrero-Ramos, MD, PhD, discusses the potential role of TAR-200 in high-risk, BCG-unresponsive, papillary-only non–muscle-invasive bladder cancer.

Dr Ghoreifi on the Feasibility for Consolidative Surgery After Enfortumab Vedotin/Pembrolizumab in Advanced Urothelial Cancer

April 28th 2025

Alireza Ghoreifi, MD, discusses the feasibility of consolidative surgery for advanced urothelial cancer receiving pembrolizumab/enfortumab vedotin.

TARA-002 Showcases Early Clinical Activity in BCG-Naive and -Unresponsive High-Risk NMIBC

April 27th 2025

Interim data from a phase 2 study support the potential of TARA-002 as an intravesical immunotherapy in high-risk NMIBC.

Neoadjuvant Mitomycin C Demonstrates Favorable Safety and Potential RFS Benefit in NMIBC

April 27th 2025

Neoadjuvant mitomycin C improved 18-month recurrence-free survival and demonstrated favorable safety in non–muscle-invasive bladder cancer.

Dr Jacob on the Potential for TAR-200 to Shift the Treatment Paradigm in NMIBC

April 27th 2025

Joseph Jacob, MD, MCR, discusses how emerging data for TAR-200 could represent a shift in the treatment paradigm for patients with high-risk non–muscle-invasive bladder cancer.

Dr Dinney on the Association Between UGDB and Cretostimogene Grenadenorepvec Response in NMIBC

April 27th 2025

Colin P.N. Dinney, MD, discusses urinary genomic disease burden as a potential biomarker for response to cretostimogene grenadenorepvec in bladder cancer.

Disitamab Vedotin/BCG Could Provide a New Bladder Sparing Therapy in HER2-Expressing High-Risk NMIBC

April 27th 2025

The addition of disitamab vedotin to BCG demonstrated high CR rates in HER2-expressing, high-risk NMIBC.

Nogapendekin Alfa Inbakicept Displays Efficacy in BCG-Unresponsive NMIBC

April 27th 2025

Nogapendekin alfa inbakicept demonstrated sustained CR rates in patients with high-risk BCG-unresponsive NMIBC.

UGN-102 May Represent Alternative to TURBT in Recurrent Low-Grade Intermediate-Risk NMIBC

April 27th 2025

UGN-102 elicits robust responses with acceptable tolerability in recurrent low-grade intermediate-risk non–muscle-invasive bladder cancer.

Consolidative Surgery Following Enfortumab Vedotin Plus Pembrolizumab Displays Efficacy in Advanced Urothelial Carcinoma

April 26th 2025

Enfortumab vedotin plus pembrolizumab followed by surgery led to high CR rates in advanced urothelial cancer.

TAR-200 Produces Unprecedented CR Rates in BCG-Unresponsive, High-Risk NMIBC

April 26th 2025

TAR-200 showed promising results in treating patients with BCG-unresponsive, high-risk NMIBC, achieving an 82.4% complete response rate.

Cretostimogene Grenadenorepvec Produces Durable CRs in High-Risk BCG-Unresponsive NMIBC

April 26th 2025

Cretostimogene grenadenorepvec generated complete responses in patients with high-risk BCG-unresponsive NMIBC and CIS with or without Ta/T1 tumors.

TAR-200 Yields Prolonged DFS in BCG-Unresponsive, Papillary High-Risk NMIBC

April 26th 2025

TAR-200 produced durable disease-free survival in BCG-unresponsive, papillary-only, high-risk non–muscle-invasive bladder cancer.

Sasanlimab Plus BCG Improves EFS in High-Risk NMIBC

April 26th 2025

Sasanlimab plus BCG significantly improved EFS vs BCG alone in high-risk non–muscle-invasive bladder cancer.

MRD Assessment Informs RFS Outcomes With Cretostimogene Grenadenorepvec in BCG-Unresponsive NMIBC

April 26th 2025

Twelve-month RFS was associated with MRD status in patients with BCG-unresponsive, NMIBC who received treatment with cretostimogene grenadenorepvec.